Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Novo Nordisk (CPSE:NOVO B) has used legal and regulatory pressure to push Hims & Hers to drop plans for a compounded oral semaglutide product.
The decision removes a potential competitor to Wegovy and Ozempic in the US weight loss and diabetes markets.
The move follows increased FDA scrutiny of compounded GLP-1 drugs that reference semaglutide.
Novo Nordisk is a major global player in diabetes and obesity treatments, with semaglutide at the center of its current product lineup. The Hims & Hers reversal underscores how important intellectual property and regulatory backing are for CPSE:NOVO B as GLP-1 drugs attract growing attention from patients and telehealth platforms.
For investors, this episode raises questions about how future competition in GLP-1 drugs may be shaped more by courts and regulators instead of quick-copy compounded products. It also puts a spotlight on pricing power, access, and how tightly brands like Wegovy and Ozempic can be protected as demand for obesity treatments evolves.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
CPSE:NOVO B 1-Year Stock Price Chart
For Novo Nordisk, forcing Hims & Hers to back away from a compounded oral semaglutide pill removes a very direct source of low price competition at a time when the company is already warning about heavy pricing pressure and a potential 5% to 13% sales decline in 2026. The FDA’s tougher stance on compounded GLP-1 drugs effectively supports Novo Nordisk’s efforts to keep semaglutide prescriptions within the approved, branded channel, which matters for both Wegovy and Ozempic, as well as the newly launched oral pill. At the same time, the lawsuit and ongoing regulatory focus introduce legal and reputational variables investors need to factor in alongside more traditional drivers such as product uptake and manufacturing capacity.
The crackdown on compounded semaglutide directly addresses one of the narrative’s key risks, where mass compounding threatened to dilute brand uptake and pressure pricing for GLP-1 drugs.
Regulatory attention on Wegovy marketing claims, and broader pricing pressure in the US, push against the thesis that expanding access through channels like telehealth will automatically support resilient earnings.
The scale and outcome of litigation against Hims & Hers, and how regulators police future copycats from players such as Eli Lilly, Pfizer or telehealth providers, are not fully captured in the existing long term story.
Story Continues
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novo Nordisk to help decide what it is worth to you.
⚠️ Legal and regulatory proceedings around semaglutide compounding, marketing practices and pricing could lead to fines, tighter promotional rules or constraints on how GLP-1 products are sold.
⚠️ Management has flagged unprecedented US pricing pressure and potential double digit sales declines for 2026, so the benefit from blocking compounded rivals sits against a weaker near term outlook.
🎁 Stronger FDA scrutiny of compounded GLP-1 drugs reduces the immediate threat from copycat pills and injectables that had been eroding Novo Nordisk’s pricing power.
🎁 The company is not only defending Wegovy and Ozempic but also advancing next generation treatments such as CagriSema, which could help keep its obesity and diabetes portfolio competitive against Eli Lilly and others.
From here, investors can monitor how the US courts handle Novo Nordisk’s lawsuit, any follow up actions from the FDA and Department of Justice on GLP-1 compounding, and whether regulators extend restrictions to injectable copycats, not just pills. It is also worth tracking how pricing agreements, especially in the US, feed through to reported sales and margins over 2026, and how quickly the oral Wegovy pill and pipeline drugs such as CagriSema gain share against Eli Lilly’s Mounjaro and Zepbound. Lastly, watch management commentary on future guidance, the DKK 15b buyback program and dividend decisions to see how confident they are that legal protections can offset pricing and competitive pressure.
To stay informed on how the latest news affects the investment narrative for Novo Nordisk, visit the community page for Novo Nordisk to keep up with the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com